Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant
By Balanced Investing : Following the successful approval and launch of Incivek, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) saw its revenue grow overnight in multiple folds in 2011. In no time, the drug crossed its
which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis
Aug 13 (Reuters) - Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.
By Small Pharma Analyst : PTC Therapeutics (NASDAQ: PTCT ) has a mission to "leverage our knowledge of RNA biology to bring novel therapeutics to patients affected by rare and neglected disorders." The science at PTC is focused on discovering drugs that address so-called "nonsense" genetic ...
In the past, I have written fairly negative assessments on the value of Vertex (NASDAQ: VRTX ). See, for instance, " Vertex Pharmaceuticals , Dog Of The Nasdaq 100 Biotechs ". While listening to the Q2 2014 analyst conference, I started
willing to sell material amounts of stock rather than maintain their shareholdings as long-term investors. Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's lead drug
Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney
including GlaxoSmithKline (9%; Morningstar Credit Rating A+), Regeneron Pharmaceuticals (8%, NR), Vertex Pharmaceuticals (7%; NR), and Beth Israel Deaconess Medical Center (5%; NR). BioMed recently derived 18% of its
Michael Kors Holdings KORS, Delta Air Lines DAL, News Corp NWSA, oil-services company Transocean RIG, and Vertex Pharmaceuticals VRTX . Meanwhile, those leaving the index included Dell, Sprint S, J.C. Penney JCP, Dean Foods DF, and